Pay in 4 interest-free payments of $6.24 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
When you use the peptides CJC-1295 and Ipamorelin together, they team up to boost your bodys growth hormone production in two key ways
Other additions to Category 1 include ruxolitinib phosphate, a JAK1and JAK2 inhibitor currently commercially available orally and topically for conditions such as myelofibrosis or atopic dermatitis respectively and dimercaprol,a chelating drug currently commercially-available as an injectable
As of April 2026, CJC-1295 and Ipamorelin have been removed from the Food and Drug Administrations (FDA) Category 2 restricted list, with formal review of compounding eligibility scheduled for July 2026
Instead, this treatment is most effective in conjunction with healthy eating and regular exercise
